Medicis Pharmaceutical Corp (NYSE:MRX)

CAPS Rating: 3 out of 5

A specialty pharmaceutical company focused on the development and marketing of products in the United States for the treatment of dermatological, aesthetic and podiatric conditions.

Recs

0
Player Avatar comet9 (< 20) Submitted: 7/13/2008 6:37:25 PM : Outperform Start Price: $18.12 MRX Score: +95.15

Slowed growth in earnings due to increased expenses with LipoSonix acquisition. Whether that business takes off or not, there is very good value here.

Featured Broker Partners


Advertisement